«After two and a half years of arbitration proceedings concerning BESREMi® (Ropeginterferon alfa-2b), the decision by the ICC Arbitral Tribunal has now been made. In 2017 PharmaEssentia had attempted to terminate the contractual agreement with AOP Orphan. The arbitral award states that the termination of the aforementioned contract was unjustified and thus that the license agreement remains in full force and effect. Consequently, AOP Orphan is entitled to payment of damages for project delays caused by PharmaEssentia, resulting in delays of the approval of the medicinal product for human use BESREMi® in Europe and delays in supply to patients affected by polycythaemia vera. On these grounds, the ICC has awarded AOP Orphan damages of a total of approximately EUR 143 million. »
ICC ruled in favor of AOP Orphan Pharmaceuticals... - MPN Voice
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
Written by
![Manouche profile image](https://images.hu-production.be/avatars/a3b96d3f503b47bbbcb94ae844837ba1_small@2x_100x100.jpg)
Manouche
To view profiles and participate in discussions please or .
2 Replies
•
![Mazcd profile image](https://images.hu-production.be/avatars/6c771cdefba9d4725ebdaae0196a8661_small@2x_100x100.jpg)
MazcdPartnerMPNVoice
important to note that drug BESREMI is approved in the EU. MPN voice has no specific additional comment
Not what you're looking for?
You may also like...
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
«We are relieved that the ICC ruling compensates AOP Orphan now for the delay in getting BESREMi®...
European Besremi legal tussle continues
« In the latest chapter in an ongoing contract dispute between AOP Orphan Pharmaceuticals GmbH and...
AOP Orphan announces 5-year results on BESREMi® in PV at the ASH Annual Meeting 2020
Besremi showed clear advantages in efficacy and safety/tolerability versus best-available-treatment...
Besremi vs Hydroxyurea
Attached is a presentation for patients regarding Besremi, in part comparing it to HU. It starts at...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
« The drug development process is not always easy or quick. It consists of drug discovery,...